Role of Single Anastomosis Gastric Bypass Surgery in Class-I Obese Diabetic Patients

Abstarct Background bariatric surgery was originally designed to induce weight-reduction in morbidly obese patients. Benefits of bariatric surgery, however, extend well beyond weight loss and include dramatic improvement of type 2 diabetes, hypertension, dyslipidemia and reduction of overall mortality. Aim of the Work to evaluate the metabolic and weight loss effect of single anastomosis gastric bypass surgery in Class-1 obese diabetic patients type-2 in the first year postoperative follow up. Patients and Methods this study included 40 mild-obese patients (Class-I) with T2DM with one or both of the following (hypertension and hyperlipidemia) treated by laparoscopic Mini-Gastric Bypass. Results the mean BMI loss after one year from MGB surgery was (6.8 ± 1.1 kg/m2). Complete resolution of diabetes occurred was in 82.5% at 12 months and cases with no remission in DM was 0%. Regarding the Hypertension, resolution of Hypertension was 63.6%. improvement was 23% and no change in Hypertension status was 13.6%. Regarding Hyperlipidemia; resolution of Hyperlipidemia was 62.5%, improvement was 21% and no change in Hypertension status was 16.5%. Conclusion bariatric surgeries (MGB) is not only a weight-reducing surgery but a metabolic surgery which can cure most of the metabolic syndrome and it is considered the most effective long term treatment modality for type 2 diabetes in mild-obese patients, our study suggests that MGB is highly effective in controlling diabetes, hypertension and hyperlipidemia.